TG THERAPEUTICS, INC. — Operating Income by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/36886799-896b-4dd6-be11-000a072f7d32/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $123.3M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-006133 |
| FY 2024 | $41.9M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-005908 |
| FY 2023 | $20.6M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-006144 |
| FY 2022 | $-218.3M | 2022-01-01 – 2022-12-31 | evidence 0001437749-25-005908 |
| FY 2021 | $-344.8M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002617 |
| FY 2020 | $-273.6M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002149 |
| FY 2019 | $-169.1M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001897 |
| FY 2018 | $-174.4M | 2018-01-01 – 2018-12-31 | evidence 0001654954-19-002189 |
| FY 2017 | $-118.7M | 2017-01-01 – 2017-12-31 | evidence 0001654954-19-002189 |
| FY 2016 | $-79.0M | 2016-01-01 – 2016-12-31 | evidence 0001654954-19-002189 |
| FY 2015 | $-63.2M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-088155 |
| FY 2014 | $-55.7M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-016369 |
| FY 2013 | $-58.3M | 2011-12-01 – 2014-03-31 | evidence 0001144204-14-030472 |
| FY 2012 | $-31.5M | 2011-12-01 – 2013-03-31 | evidence 0001144204-13-028722 |
| FY 2011 | $-18.3M | 2011-04-01 – 2012-03-31 | evidence 0001144204-12-028735 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).